<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: additional losses as", fill: "#ff004f"},
{source: "4: additional losses as", target: "4: development", fill: "#ff004f"},
{source: "4: development", target: "4: bremelanotide", fill: "#ff004f"},
{source: "4: bremelanotide", target: "4: product candidates", fill: "#ff004f"},
{source: "4: additional losses as", target: "6: Therefore ", fill: "#dea5a4"},
{source: "6: Therefore ", target: "6: foreseeable future", fill: "#dea5a4"},
{source: "6: foreseeable future", target: "6: operations", fill: "#dea5a4"},
{source: "6: operations", target: "6: capital expenditures from reimbursements", fill: "#dea5a4"},
{source: "6: capital expenditures from reimbursements", target: "6: existing collaborative development", fill: "#dea5a4"},
{source: "6: existing collaborative development", target: "6: agreements existing cash balances", fill: "#dea5a4"},
{source: "6: agreements existing cash balances", target: "6: outside sources", fill: "#dea5a4"},
{source: "6: outside sources", target: "6: financing which", fill: "#dea5a4"},
{source: "6: financing which", target: "6: available on", fill: "#dea5a4"},
{source: "6: Therefore ", target: "7: raising additional funds on", fill: "#d73b3e"},
{source: "7: raising additional funds on", target: "7: clinical trials", fill: "#d73b3e"},
{source: "7: clinical trials", target: "7: candidates from", fill: "#d73b3e"},
{source: "7: candidates from", target: "7: regulatory authorities", fill: "#d73b3e"},
{source: "7: raising additional funds on", target: "11: operations provide", fill: "#9b111e"},
{source: "11: operations provide", target: "11: commercialize", fill: "#9b111e"},
{source: "11: commercialize", target: "11: candidates", fill: "#9b111e"},
{source: "11: operations provide", target: "12: yet demonstrated", fill: "#efcc00"},
{source: "12: yet demonstrated", target: "12: necessary", fill: "#efcc00"},
{source: "12: necessary", target: "12: successful commercialization", fill: "#efcc00"},
{source: "12: successful commercialization", target: "12: candidates", fill: "#efcc00"},
{source: "12: yet demonstrated", target: "13: successful commercialization", fill: "#e75480"},
{source: "13: successful commercialization", target: "13: product candidates will", fill: "#e75480"},
{source: "13: product candidates will", target: "13: conduct preclinical development", fill: "#e75480"},
{source: "13: conduct preclinical development", target: "13: clinical trials", fill: "#e75480"},
{source: "13: clinical trials", target: "13: participating", fill: "#e75480"},
{source: "13: participating", target: "13: regulatory approval processes", fill: "#e75480"},
{source: "13: regulatory approval processes", target: "13: formulating", fill: "#e75480"},
{source: "13: formulating", target: "13: manufacturing products", fill: "#e75480"},
{source: "13: manufacturing products", target: "13: third parties formulate", fill: "#e75480"},
{source: "13: third parties formulate", target: "13: manufacture product", fill: "#e75480"},
{source: "13: manufacture product", target: "13: conducting sales", fill: "#e75480"},
{source: "13: conducting sales", target: "13: marketing activities either alone", fill: "#e75480"},
{source: "13: marketing activities either alone", target: "13: additional capital", fill: "#e75480"},
{source: "13: successful commercialization", target: "18: market acceptance", fill: "#fdf5e6"},
{source: "18: market acceptance", target: "18: such product will depend on", fill: "#fdf5e6"},
{source: "18: such product will depend on", target: "18: perceptions by members", fill: "#fdf5e6"},
{source: "18: perceptions by members", target: "18: healthcare community", fill: "#fdf5e6"},
{source: "18: healthcare community", target: "18: effectiveness", fill: "#fdf5e6"},
{source: "18: effectiveness", target: "18: costeffectiveness relative", fill: "#fdf5e6"},
{source: "18: costeffectiveness relative", target: "18: competing products", fill: "#fdf5e6"},
{source: "18: competing products", target: "18: technologies", fill: "#fdf5e6"},
{source: "18: technologies", target: "18: availability", fill: "#fdf5e6"},
{source: "18: availability", target: "18: reimbursement", fill: "#fdf5e6"},
{source: "18: reimbursement", target: "18: products from government", fill: "#fdf5e6"},
{source: "18: products from government", target: "18: healthcare payors", fill: "#fdf5e6"},
{source: "18: healthcare payors", target: "18: advantages over alternative treatment methods", fill: "#fdf5e6"},
{source: "18: market acceptance", target: "19: voluntarily withdrew", fill: "#f88379"},
{source: "19: voluntarily withdrew", target: "19: NeutroSpec ", fill: "#f88379"},
{source: "19: NeutroSpec ", target: "19: difficult", fill: "#f88379"},
{source: "19: difficult", target: "19: gain market acceptance with", fill: "#f88379"},
{source: "19: gain market acceptance with", target: "19: reintroduced", fill: "#f88379"},
{source: "19: voluntarily withdrew", target: "38: Government ", fill: "#abcdef"},
{source: "38: Government ", target: "38: regulation may delay", fill: "#abcdef"},
{source: "38: regulation may delay", target: "38: prevent marketing", fill: "#abcdef"},
{source: "38: prevent marketing", target: "38: potential products", fill: "#abcdef"},
{source: "38: potential products", target: "38: impose costly", fill: "#abcdef"},
{source: "38: impose costly", target: "38: procedures upon", fill: "#abcdef"},
{source: "38: procedures upon", target: "38: activities", fill: "#abcdef"},
{source: "38: Government ", target: "START_HERE", fill: "#abcdef"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Oil and Gas Exploration and Production</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_Trials_Directive">Clinical Trials Directive</a></td>
      <td>The Clinical Trials Directive (Officially Directive 2001/20/EC of 4 April 2001, of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use) is a European Union directive that aimed at facilitating the internal market in medicinal products within the European Union, while at the same time maintaining an appropriate level of protection for public health. It seeks to simplify and harmonise the administrative provisions governing clinical trials in the European Community, by establishing a clear, transparent procedure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Analysis_of_clinical_trials">Analysis of clinical trials</a></td>
      <td>The analysis of clinical trials involves many related topics including:\n\nthe choice of an estimand (measure of effect size) of interest that is closely linked to the objectives of the trial,\nthe choice and definition of analysis sets,\nthe choice of an appropriate statistical model for the type of data being studied,\nappropriate accounting for the treatment assignment process,\nhandling of missing data,\nhandling of multiple comparisons or endpoints,\naccounting for interim analyses and trial adaptations,\nand appropriate data presentation.One basic guidance document on this topic is the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidance E9.\n\n\n== Choice of analysis set ==\nFailure to include all participants in the analysis may bias the trial results.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_of_the_2022_Australian_federal_election">Candidates of the 2022 Australian federal election</a></td>
      <td>This is a list of confirmed candidates in ballot paper order for the 2022 Australian federal election.At the close of nominations a total of 1,624 candidates had stood for election, of which 1,203 were House of Representatives candidates and 421 were Senate candidates.\n\n\n== Retiring members ==\nThe seat of Spence (SA) was vacant following the resignation of Nick Champion (Labor) on 22 February 2022 to contest the South Australian state election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Officer_candidate">Officer candidate</a></td>
      <td>Officer candidate or officer aspirant (OA) is a rank in some militaries of the world that is an appointed position while a person is in training to become an officer.  More often than not, an officer candidate was a civilian who applied to join the military directly as an officer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technetium_(99mTc)_fanolesomab">Technetium (99mTc) fanolesomab</a></td>
      <td>Technetium (99mTc) fanolesomab (trade name NeutroSpec, manufactured by Palatin Technologies) is a mouse monoclonal antibody formerly used to aid in the diagnosis of appendicitis. It is labeled with a radioisotope, technetium-99m (99mTc).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_therapeutic_monoclonal_antibodies">List of therapeutic monoclonal antibodies</a></td>
      <td>This is a list of therapeutic, diagnostic and preventive monoclonal antibodies, antibodies that are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_sexual_activity">Human sexual activity</a></td>
      <td>Human sexual activity, human sexual practice or human sexual behaviour is the manner in which humans experience and express their sexuality. People engage in a variety of sexual acts, ranging from activities done alone (e.g., masturbation) to acts with another person (e.g., sexual intercourse, non-penetrative sex, oral sex, etc.) in varying patterns of frequency, for a wide variety of reasons.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Extracurricular_activity">Extracurricular activity</a></td>
      <td>An extracurricular activity (ECA) or extra academic activity (EAA) or cultural activities is an activity, performed by students, that falls outside the realm of the normal curriculum of school, college or university education. Such activities are generally voluntary (as opposed to mandatory), social, philanthropic, and often involve others of the same age.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Activity_diagram">Activity diagram</a></td>
      <td>Activity diagrams are graphical  representations of workflows of stepwise activities and actions with support for choice, iteration and concurrency. In the Unified Modeling Language, activity diagrams are intended to model both computational and organizational processes (i.e., workflows), as well as the data flows intersecting with the related activities.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Paranormal_Activity">Paranormal Activity</a></td>
      <td>Paranormal Activity is a 2007 American supernatural horror film produced, written, directed, photographed and edited by Oren Peli. It centers on a young couple (Katie Featherston and Micah Sloat) who are haunted by a supernatural presence in their home.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Student_activities">Student activities</a></td>
      <td>Student activities (also known as campus activities) are student-focused extracurricular clubs and programs offered at a college or university. Student activities are generally designed to allow students to become more involved on campus.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Extravehicular_activity">Extravehicular activity</a></td>
      <td>Extravehicular activity (EVA) is any activity done by an astronaut outside a spacecraft beyond the Earth's appreciable atmosphere. Normally, the term applies to what has been termed a spacewalk outside a craft that is orbiting Earth (such as the International Space Station).</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>PALATIN TECHNOLOGIES INC      Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>We expect to continue to incur substantial <font color="blue">losses over</font> the <font color="blue">next few years</font>     and we <font color="blue">may never become profitable</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">never been profitable</font> and we <font color="blue">may never become profitable</font></td>
    </tr>
    <tr>
      <td>We     expect  to  incur  <font color="blue"><font color="blue">additional</font> losses as</font> we continue our <font color="blue">development</font> of     <font color="blue">bremelanotide</font> and our other <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Unless and until we receive     approval from the FDA or other <font color="blue">equivalent <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font> outside</font> the     United  States,  we <font color="blue">cannot sell</font> our products and will not have product     <font color="blue">revenues from them</font></td>
    </tr>
    <tr>
      <td>Therefore, for the <font color="blue">foreseeable future</font>, we will have to     fund all of our <font color="blue">operations</font> and <font color="blue">capital <font color="blue">expenditures</font> from <font color="blue">reimbursement</font>s</font> and     other  contract  revenue  under our existing <font color="blue">collaborative</font> <font color="blue">development</font>     <font color="blue">agreement</font>s, existing cash balances and <font color="blue">outside sources</font> of financing, which     may not be <font color="blue">available on</font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>If we do not succeed in     <font color="blue">raising <font color="blue">additional</font> funds on</font> acceptable terms, we may be unable to complete     planned pre-clinical and <font color="blue">clinical trials</font> or obtain approval of our product     <font color="blue"><font color="blue">candidates</font> from</font> the FDA or other <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font></td>
    </tr>
    <tr>
      <td>In addition, we     could be forced to suspend or <font color="blue">discontinue</font> our product <font color="blue">development</font> programs     and <font color="blue">forego attractive</font> business opportunities, which would have a material     adverse effect on our business</td>
    </tr>
    <tr>
      <td>We  have  a limited operating <font color="blue">history upon which</font> to base an <font color="blue">investment</font>     decision</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> to date have <font color="blue">been primarily focused on</font> organizing and     staffing our Company, acquiring, developing and securing our <font color="blue">proprietary</font>     <font color="blue">technology</font>, conducting pre-clinical and <font color="blue">clinical studies</font> and <font color="blue">formulating</font> and     <font color="blue">manufacturing</font> our principal <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>These <font color="blue">operations</font> provide a     limited basis for you to assess our ability to <font color="blue">commercialize</font> our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We have not <font color="blue">yet <font color="blue">demonstrate</font>d</font> our ability to perform the functions     <font color="blue">necessary</font>  for  the <font color="blue">successful <font color="blue">commercialization</font></font> of any of our product     <font color="blue">candidates</font> other than NeutroSpec</td>
    </tr>
    <tr>
      <td>The <font color="blue">successful <font color="blue">commercialization</font></font> of our     other <font color="blue">product <font color="blue">candidates</font></font> will require us to perform a variety of functions,     including:       • continuing to conduct pre-clinical <font color="blue">development</font> and <font color="blue">clinical trials</font>;     • <font color="blue">participating</font> in <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font> processes</font>;     • <font color="blue">formulating</font> and <font color="blue">manufacturing</font> products, or having <font color="blue"><font color="blue">third parties</font> formulate</font>     and <font color="blue">manufacture product</font>;     • <font color="blue">conducting sales</font> and marketing <font color="blue">activities</font>, either alone or with a partner;     and     • obtaining <font color="blue"><font color="blue">additional</font> capital</font></td>
    </tr>
    <tr>
      <td>If we are unable to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> of any of our product     <font color="blue">candidates</font>, or to <font color="blue">successfully</font> <font color="blue">commercialize</font> any products for which we     receive <font color="blue"><font color="blue">regulatory</font> approval</font>, we may not be able to recover our <font color="blue">investment</font> in     our <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>If any approved product does not achieve market <font color="blue">acceptance</font>, our business     will suffer</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font>approval for the marketing and sale of any of our product     <font color="blue">candidates</font> does not assure the product’s commercial success</td>
    </tr>
    <tr>
      <td>Any approved     <font color="blue">product will compete with</font> other <font color="blue">products manufactured</font> and marketed                                         9       _________________________________________________________________       [30]Table of <font color="blue">Contents       </font><font color="blue">by major pharmaceutical</font> and other <font color="blue">bio<font color="blue">technology</font> companies</font></td>
    </tr>
    <tr>
      <td>The degree of     market <font color="blue">acceptance</font> of any <font color="blue">such product will <font color="blue">depend on</font></font> a number of factors,     including:       • <font color="blue">perceptions by members</font> of the <font color="blue">healthcare community</font>, including physicians,     about its safety and <font color="blue"><font color="blue">effective</font>ness</font>;     • cost-<font color="blue"><font color="blue">effective</font>ness</font> relative to <font color="blue">competing products</font> and <font color="blue">technologies</font>;     • <font color="blue">availability</font> of <font color="blue">reimbursement</font> for our <font color="blue">products from <font color="blue">government</font></font> or other     <font color="blue">healthcare payors</font>;     • <font color="blue">advantages over <font color="blue">alternative</font> treatment methods</font></td>
    </tr>
    <tr>
      <td>Because we <font color="blue">voluntarily withdrew</font> <font color="blue">NeutroSpec </font>from the market, it may     be more <font color="blue">difficult</font> to gain market <font color="blue">acceptance</font> with NeutroSpec, assuming that     the FDA permits <font color="blue">NeutroSpec </font>to be <font color="blue">reintroduced</font> to the market</td>
    </tr>
    <tr>
      <td>If any approved product does not achieve adequate market <font color="blue">acceptance</font>,     our  business,  financial  condition and results of <font color="blue">operations</font> will be     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td><font color="blue">Development  </font>and <font color="blue">commercialization</font> of our <font color="blue">proposed products</font> involves a     lengthy, complex and <font color="blue">costly process</font> and we may never <font color="blue">successfully</font> develop or     <font color="blue">commercialize</font> any product</td>
    </tr>
    <tr>
      <td>Our  product  <font color="blue">candidates</font> are <font color="blue">at various stages</font> of research and     <font color="blue">development</font>, will require <font color="blue"><font color="blue">regulatory</font> approval</font>, and may never be <font color="blue">successfully</font>     developed or <font color="blue">commercialize</font>d</td>
    </tr>
    <tr>
      <td>Our <font color="blue">products will</font> require <font color="blue"><font color="blue">significant</font> further</font>     research, <font color="blue">development</font> and testing before we can seek <font color="blue"><font color="blue">regulatory</font> approval</font> to     market and sell them</td>
    </tr>
    <tr>
      <td>You <font color="blue">should evaluate us</font> in light of the <font color="blue">uncertainties</font>,     delays,  <font color="blue">difficult</font>ies and <font color="blue">expenses commonly</font> experienced <font color="blue">by early stage</font>     <font color="blue"><font color="blue">biopharmaceutical</font> companies</font>, including <font color="blue">unanticipated problems</font> and <font color="blue">additional</font>     costs relating to:       • the research, <font color="blue">development</font> and testing of products in animals and humans;     • <font color="blue">product approval</font> or clearance;     • <font color="blue"><font color="blue">regulatory</font> compliance</font>;     • good <font color="blue">manufacturing</font> practices;     • <font color="blue"><font color="blue">intellectual</font> property rights</font>;     • <font color="blue">product introduction</font>; and     • marketing and <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">regulatory</font> approval</font> process is lengthy, expensive and uncertain, and may     <font color="blue">prevent us from</font> obtaining the approvals we require</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font><font color="blue">authorities</font> in the <font color="blue">United States </font>and other countries     <font color="blue">extensively regulate</font> the advertising, labeling, storage, record-keeping,     safety, efficacy, research, <font color="blue">development</font>, testing, manufacture, promotion,     marketing and <font color="blue">distribution</font> of <font color="blue">drug products</font></td>
    </tr>
    <tr>
      <td>Drugs are subject to rigorous     <font color="blue">regulation by</font> the FDA in the <font color="blue">United States </font>and similar <font color="blue">regulatory</font> bodies in     other countries</td>
    </tr>
    <tr>
      <td>The steps ordinarily required by the FDA before a new drug     may be marketed in the <font color="blue">United States </font>include:       • <font color="blue">completion</font> of pre-clinical <font color="blue">laboratory</font> tests, pre-clinical trial and     <font color="blue">formulation studies</font>;     • submission to the FDA of an <font color="blue">investigational <font color="blue">new drug <font color="blue">application</font></font></font>, or IND,     <font color="blue">which must become</font>     <font color="blue">effective</font> before <font color="blue">clinical trials</font> may begin;     • performance of adequate and well-controlled human <font color="blue">clinical trials</font> to     establish the safety and     efficacy of the drug for <font color="blue">each proposed <font color="blue">indication</font></font>;     • the submission of a <font color="blue">new drug <font color="blue">application</font></font>, or NDA, to the FDA; and     • FDA review and approval of the NDA before any <font color="blue">commercial marketing</font> or     sale</td>
    </tr>
    <tr>
      <td>The  results  of product <font color="blue">development</font>, pre-<font color="blue">clinical studies</font> and     <font color="blue">clinical studies</font> are submitted to the FDA as part of a <font color="blue">NDA The NDA </font>also     must contain extensive <font color="blue">manufacturing</font> information</td>
    </tr>
    <tr>
      <td>Once the submission has     been accepted for filing, the FDA <font color="blue">generally</font> has ten months to review the     <font color="blue">application</font>  and respond to the applicant</td>
    </tr>
    <tr>
      <td>The <font color="blue">review process</font> is often     <font color="blue"><font color="blue">significant</font>ly</font>  extended  by FDA requests for <font color="blue">additional</font> information or     <font color="blue">clarification</font></td>
    </tr>
    <tr>
      <td>The FDA may refer the NDA to an advisory committee for     review, evaluation and <font color="blue">recommendation</font> as to whether the <font color="blue">application</font> should     be approved, but the FDA is not bound by the <font color="blue">recommendation</font> of an advisory     committee</td>
    </tr>
    <tr>
      <td>The FDA may deny or <font color="blue">delay approval</font> of <font color="blue">application</font>s that do not     meet applicable <font color="blue">regulatory</font> criteria or if the <font color="blue">FDA                                         </font>10       _________________________________________________________________       [31]Table of <font color="blue">Contents       </font>determines that the <font color="blue">clinical data</font> do not <font color="blue">adequately establish</font> the safety and     efficacy of the drug</td>
    </tr>
    <tr>
      <td>Upon approval, a <font color="blue">drug candidate may</font> be <font color="blue">marketed only</font>     in those <font color="blue">dosage forms</font> and for those <font color="blue"><font color="blue">indication</font>s approved by</font> the FDA Once     approved, the FDA <font color="blue">may withdraw</font> the <font color="blue">product approval</font> if <font color="blue">compliance with pre</font>-     and post-market <font color="blue">regulatory</font> standards is not maintained or if problems occur     after the <font color="blue">product reaches</font> the marketplace</td>
    </tr>
    <tr>
      <td>In addition, the FDA may require     post-marketing studies, referred to as Phase 4 studies, to monitor the     effect of <font color="blue">approved products</font>, and <font color="blue">may limit further marketing</font> of the product     based  on  the results of these post-market studies</td>
    </tr>
    <tr>
      <td>The FDA has broad     post-market <font color="blue">regulatory</font> and <font color="blue">enforcement powers</font>, including the ability to levy     fines and civil penalties, suspend or <font color="blue">delay issuance</font> of approvals, seize or     <font color="blue">recall products</font>, and <font color="blue">withdraw approvals</font></td>
    </tr>
    <tr>
      <td><font color="blue">Satisfaction of FDA </font>pre-market approval <font color="blue">requirements</font> for new drugs     typically takes <font color="blue">several years</font> and the actual time required for <font color="blue">approval may</font>     vary  <font color="blue"><font color="blue">substantially</font> based upon</font> the type, <font color="blue">complexity</font> and novelty of the     product or disease</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font><font color="blue">regulation may delay</font> or <font color="blue">prevent marketing</font> of     <font color="blue">potential products</font> for a considerable period of time and <font color="blue">impose costly</font>     <font color="blue">procedures upon</font> our <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Data obtained from     clinical <font color="blue">activities</font> is not <font color="blue">always conclusive</font> and may be susceptible to     varying  <font color="blue">interpretations</font> that could delay, limit or prevent <font color="blue">regulatory</font>     approval</td>
    </tr>
    <tr>
      <td>Even if a product receives <font color="blue"><font color="blue">regulatory</font> approval</font>, later discovery of     <font color="blue">previously unknown problems with</font> a <font color="blue">product may</font> result in <font color="blue">restrictions on</font> the     product or even complete withdrawal of the <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">regulatory</font> approval</font> of any of our products is granted, it will be     limited  to <font color="blue">certain disease</font> states or <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">manufacturer</font>s</font> of     <font color="blue">approved products</font> and their <font color="blue">manufacturing</font> <font color="blue">facilities</font> will be subject to     <font color="blue">continual review</font> and <font color="blue">periodic inspections by</font> the FDA and other <font color="blue">authorities</font>     where applicable, and must comply with ongoing <font color="blue">regulatory</font> <font color="blue">requirements</font>,     including the FDA’s <font color="blue">cGMP <font color="blue">regulations</font></font></td>
    </tr>
    <tr>
      <td>Failure to comply with the statutory     and <font color="blue">regulatory</font> <font color="blue">requirements</font> subjects the <font color="blue">manufacturer</font> to possible legal or     <font color="blue">regulatory</font> action, such as Warning Letters, suspension of <font color="blue">manufacturing</font>,     seizure of product, voluntary recall of a product, injunctive action or     <font color="blue">possible civil penalties</font></td>
    </tr>
    <tr>
      <td>Adverse experiences with the <font color="blue">product must</font> be     reported to the FDA and could result in the imposition of <font color="blue">market restriction</font>     <font color="blue">through labeling</font> changes or in <font color="blue">product removal</font></td>
    </tr>
    <tr>
      <td>Product approvals may be     withdrawn if compliance with <font color="blue">regulatory</font> <font color="blue">requirements</font> is not maintained or if     problems  <font color="blue">concerning safety</font> or efficacy of the product occur following     approval</td>
    </tr>
    <tr>
      <td>Because we intend to <font color="blue">contract with <font color="blue">third parties</font></font> for <font color="blue">manufacturing</font>     of these products, our ability to <font color="blue">control <font color="blue">third party</font> compliance with</font> FDA     <font color="blue">requirements</font>  will  be  limited  to <font color="blue"><font color="blue">contractual</font> remedies</font> and rights of     inspection</td>
    </tr>
    <tr>
      <td>Failure of third-party <font color="blue"><font color="blue">manufacturer</font>s</font> to comply with cGMP or     <font color="blue">other FDA </font><font color="blue">requirements</font> may result in legal or <font color="blue">regulatory</font> action by the FDA               Outside the United States, our ability to market our <font color="blue">products will</font>     <font color="blue">also <font color="blue">depend on</font></font> receiving <font color="blue">marketing <font color="blue">authorization</font>s from</font> the <font color="blue">appropriate</font>     <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font></td>
    </tr>
    <tr>
      <td>The foreign <font color="blue"><font color="blue">regulatory</font> approval</font> process includes all     of the <font color="blue">risks associated with</font> FDA <font color="blue">approval described</font> above</td>
    </tr>
    <tr>
      <td>The <font color="blue">requirements</font>     governing the conduct of <font color="blue">clinical trials</font> and <font color="blue">marketing <font color="blue">authorization</font> vary</font>     <font color="blue">widely from country</font> to country</td>
    </tr>
    <tr>
      <td>At present, foreign marketing <font color="blue">authorization</font>s     are applied for at a national level, although within the European Community,     or EC, <font color="blue">registration procedures</font> are available to companies wishing to market     a product to more than one EC member state</td>
    </tr>
    <tr>
      <td>If the <font color="blue">regulatory</font> authority is     satisfied that adequate evidence of safety, quality and <font color="blue">efficiency</font> has been     presented, a marketing <font color="blue">authorization</font> will be granted</td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> to reintroduce <font color="blue">NeutroSpec </font>    to the market, or may be required to conduct extensive <font color="blue">clinical trials</font> prior     to <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td><font color="blue">NeutroSpec </font>was <font color="blue">initially approved by</font> the FDA for imaging of patients     with equivocal signs and symptoms of <font color="blue">appendicitis</font></td>
    </tr>
    <tr>
      <td>However, the reported     serious  adverse events were associated with off-label use (use for an     <font color="blue">indication</font> other <font color="blue">than diagnosis</font> of equivocal <font color="blue">appendicitis</font>), and substantial     sales of <font color="blue">NeutroSpec </font>were for off-label uses</td>
    </tr>
    <tr>
      <td>We are conducting <font color="blue">additional</font>     <font color="blue"><font color="blue">laboratory</font> studies</font> to understand the <font color="blue"><font color="blue">relationship</font> between</font> <font color="blue">NeutroSpec </font>and     reported serious adverse events</td>
    </tr>
    <tr>
      <td>We may not be able to develop a sufficient     understanding of the <font color="blue">relationship</font> to warrant <font color="blue">application</font> to the FDA to     conduct <font color="blue">additional</font> studies or remarket the product</td>
    </tr>
    <tr>
      <td>We may also not be able     to develop methods, formulations or protocols that permit <font color="blue">NeutroSpec </font>to be     used  safely</td>
    </tr>
    <tr>
      <td>We  also do not know whether the FDA <font color="blue">will concur</font> in our     risk/benefit assessment of NeutroSpec, or permit <font color="blue">NeutroSpec </font>to be marketed     again</td>
    </tr>
    <tr>
      <td>Even if we seek to reintroduce <font color="blue">NeutroSpec </font>to the market, we may seek     approval to market <font color="blue">NeutroSpec </font>for other <font color="blue">indication</font>s, such as osteomyelitis     (<font color="blue">infection deep</font> inside a bone), which will require that Phase 2 and Phase 3     <font color="blue">clinical trials</font> be <font color="blue">successfully</font> completed prior to <font color="blue">seeking approval</font> of the     FDA       We  rely  on  <font color="blue">third parties</font> to conduct <font color="blue">clinical trials</font> for our product     <font color="blue">candidates</font> and their failure to timely perform their <font color="blue">obligations could</font>     <font color="blue"><font color="blue">significant</font>ly</font> harm our product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We rely on outside scientific <font color="blue">collaborators</font> such as researchers at     <font color="blue">clinical research organizations</font> and <font color="blue">universities</font> in <font color="blue">certain areas</font> that are     <font color="blue">particularly relevant</font> to our research and product <font color="blue">development</font> plans, such as     the conduct of <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">competition</font> for these <font color="blue">relationship</font>s is     intense, and we may not be able to maintain our                                         11       _________________________________________________________________       [32]Table of <font color="blue">Contents       </font><font color="blue">relationship</font>s with them on acceptable terms</td>
    </tr>
    <tr>
      <td>These <font color="blue">outside <font color="blue">collaborators</font></font>     <font color="blue">generally</font> may terminate their <font color="blue">engagements with us at</font> any time</td>
    </tr>
    <tr>
      <td>As a result,     we can control their <font color="blue">activities</font> only within certain limits, and they will     devote  only a certain amount of their time to conduct research on our     <font color="blue">product <font color="blue">candidates</font></font> and develop them</td>
    </tr>
    <tr>
      <td>If they do not <font color="blue">successfully</font> carry out     their <font color="blue">duties under</font> their <font color="blue">agreement</font>s with us, fail to <font color="blue">inform us</font> if these     <font color="blue">trials fail</font> to <font color="blue">comply with clinical trial protocols</font> or fail to meet expected     <font color="blue">deadlines</font>, this may <font color="blue">adversely</font> affect our ability to develop our product     <font color="blue">candidates</font> and obtain <font color="blue"><font color="blue">regulatory</font> approval</font> on a <font color="blue">timely basis</font> if at all</td>
    </tr>
    <tr>
      <td>The results of our <font color="blue">clinical trials</font> may not support our product claims</td>
    </tr>
    <tr>
      <td>Even if our <font color="blue">clinical trials</font> are completed as planned, we cannot be     certain that their results <font color="blue">will support</font> our product claims</td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical trial process may fail</font> to <font color="blue">demonstrate</font>     that our <font color="blue">product <font color="blue">candidates</font></font> are safe for humans and <font color="blue">effective</font> for indicated     uses</td>
    </tr>
    <tr>
      <td>This <font color="blue">failure would</font> cause us to abandon a <font color="blue">product candidate</font> and could     delay <font color="blue">development</font> of other <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Any delay in, or <font color="blue">termination</font>     of, our <font color="blue">clinical trials</font> will delay or eliminate our ability to <font color="blue">commercialize</font>     our <font color="blue">product <font color="blue">candidates</font></font> and <font color="blue">generate product revenues</font></td>
    </tr>
    <tr>
      <td><font color="blue">Production </font>and supply of <font color="blue">bremelanotide</font> and <font color="blue">NeutroSpec </font><font color="blue"><font color="blue">depend on</font> contract</font>     <font color="blue"><font color="blue">manufacturer</font>s</font> over whom we have no control</td>
    </tr>
    <tr>
      <td>We  do  not  have the <font color="blue">facilities</font> to manufacture <font color="blue">bremelanotide</font>,     <font color="blue">NeutroSpec </font>or our other <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our contract <font color="blue"><font color="blue">manufacturer</font>s</font> must     perform these <font color="blue">manufacturing</font> <font color="blue">activities</font> in a manner that <font color="blue">complies with</font> FDA     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Failure to conduct their <font color="blue">activities</font> in compliance with FDA     <font color="blue">regulations</font> could delay our <font color="blue">development</font> programs or <font color="blue">negatively impact</font> our     ability to receive FDA approval of our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Establishing     </font><font color="blue">relationship</font>s  with  new  suppliers,  who  must  be FDA-approved, is a     time-consuming and <font color="blue">costly process</font></td>
    </tr>
    <tr>
      <td>We are subject to extensive regulation in <font color="blue">connection with</font> the <font color="blue">laboratory</font>     practices and the <font color="blue"><font color="blue">hazardous</font> materials</font> we use</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">various laws</font> and <font color="blue">regulations</font> regarding <font color="blue">laboratory</font>     practices, the <font color="blue">experimental use</font> of animals and the use and disposal of     <font color="blue">hazardous</font>  or  <font color="blue">potentially</font> <font color="blue">hazardous</font> substances in <font color="blue">connection with</font> our     research</td>
    </tr>
    <tr>
      <td>In  each  of these areas, as noted above, the FDA and other     <font color="blue">regulatory</font>  <font color="blue">authorities</font>  have broad <font color="blue">regulatory</font> and <font color="blue">enforcement powers</font>,     including the ability to levy fines and civil penalties, suspend or delay     issuance of approvals, seize or <font color="blue">recall products</font> and <font color="blue">withdraw approvals</font>, any     one or more of <font color="blue">which could</font> have a material adverse effect upon us</td>
    </tr>
    <tr>
      <td>We are     also subject to <font color="blue">numerous federal</font>, state and <font color="blue">local laws</font> relating to such     <font color="blue">matters as safe</font> working <font color="blue">conditions</font>, <font color="blue">manufacturing</font> practices, environmental     protection, fire hazard control and disposal of <font color="blue">hazardous</font> or <font color="blue">potentially</font>     <font color="blue">hazardous</font> substances</td>
    </tr>
    <tr>
      <td>We <font color="blue">may incur <font color="blue">significant</font> costs</font> to <font color="blue">comply with such</font>     laws and <font color="blue">regulations</font> now or in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Contamination </font>or <font color="blue">injury from</font> <font color="blue"><font color="blue">hazardous</font> materials</font> used in the <font color="blue">development</font> of     our <font color="blue">products could</font> result in a <font color="blue"><font color="blue">liability</font> exceeding</font> our <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> involves the use of <font color="blue"><font color="blue">hazardous</font> materials</font>     and  <font color="blue">chemicals</font>,  including <font color="blue">radioactive compounds</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot completely</font>     eliminate the risk of <font color="blue">contamination</font> or <font color="blue">injury from</font> these materials</td>
    </tr>
    <tr>
      <td>In the     event of <font color="blue">contamination</font> or injury, we may be responsible for any resulting     damages</td>
    </tr>
    <tr>
      <td><font color="blue">Damages  </font>could be <font color="blue">significant</font> and <font color="blue">could exceed</font> our financial     resources, including the limits of our insurance</td>
    </tr>
    <tr>
      <td>We have limited or no experience in marketing, <font color="blue">distributing</font> and selling     products and <font color="blue">will <font color="blue">substantially</font> rely on</font> our <font color="blue">marketing partners</font> to provide     these <font color="blue">cap<font color="blue">abilities</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>approves <font color="blue">bremelanotide</font> for marketing and sale, we will     <font color="blue">depend on</font> our <font color="blue"><font color="blue">arrangement</font>s with</font> King for the marketing, <font color="blue">distribution</font> and     sale of <font color="blue">bremelanotide</font></td>
    </tr>
    <tr>
      <td>If King fails to market <font color="blue">bremelanotide</font> or devote     <font color="blue">enough resources</font> to <font color="blue">bremelanotide</font>, our <font color="blue"><font color="blue">potential revenues</font> from</font> the sale of     <font color="blue">bremelanotide</font> will be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>If these <font color="blue"><font color="blue">arrangement</font>s fail</font>, we may     have <font color="blue">difficult</font>y establishing new marketing <font color="blue">relationship</font>s, and in any event,     we will have limited <font color="blue">control over</font> these <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If  we  recommence  sales  of  NeutroSpec,  we  will <font color="blue">depend on</font>     Mallinckrodt, our <font color="blue">strategic collaboration partner</font>, to market, sell and     distribute the product</td>
    </tr>
    <tr>
      <td>If <font color="blue">Mallinckrodt </font>fails to market <font color="blue">NeutroSpec </font>or devote     <font color="blue">enough resources</font> to NeutroSpec, our <font color="blue"><font color="blue">potential revenues</font> will</font> be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>If the <font color="blue">arrangement</font> with <font color="blue">Mallinckrodt </font>fails, we may have <font color="blue">difficult</font>y     establishing new marketing <font color="blue">relationship</font>s, and in any event, we will have     limited <font color="blue">control over</font> these <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>12       _________________________________________________________________       [33]Table of <font color="blue">Contents       </font>Competing  products  and  <font color="blue">technologies</font>  may make our <font color="blue">proposed products</font>     <font color="blue">non<font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td>We are aware of three oral FDA-approved PDE-5 <font color="blue">inhibitor drugs</font> for     the treatment of <font color="blue">erectile dysfunction</font></td>
    </tr>
    <tr>
      <td>These products are <font color="blue">also approved</font> in     Europe, Japan and most of the world’s pharmaceutical markets</td>
    </tr>
    <tr>
      <td>In addition,     other products are being developed for <font color="blue">ED and FSD In </font>order to achieve     approval and market <font color="blue">acceptance</font>, <font color="blue">bremelanotide</font> may <font color="blue">potentially</font> be required to     <font color="blue">demonstrate</font>  efficacy and <font color="blue">safety equivalent</font> or superior to these other     products</td>
    </tr>
    <tr>
      <td>We are aware of <font color="blue">one company</font> developing a <font color="blue">technetium imaging product</font>     and another <font color="blue">company marketing</font> an antibody-based technetium product in some     European countries, both of <font color="blue">which may compete with</font> <font color="blue">NeutroSpec </font>for certain     <font color="blue">indication</font>s</td>
    </tr>
    <tr>
      <td>In addition, other <font color="blue">technologies</font> may also be used to diagnose     <font color="blue">appendicitis</font>, osteomyelitis and other infection-related diseases, including     CT and ultrasound <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">biopharmaceutical</font>  and  <font color="blue">diagnostic</font>  <font color="blue">industries</font> are highly     <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>We are likely to encounter <font color="blue">significant</font> <font color="blue">competition</font> with respect     to <font color="blue">bremelanotide</font>, <font color="blue">NeutroSpec </font>and our other <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>Many of our     <font color="blue">competitors</font> have <font color="blue">substantially</font> greater financial and <font color="blue">technological</font> resources     than we do</td>
    </tr>
    <tr>
      <td>Many of them also have <font color="blue"><font color="blue">significant</font>ly</font> greater experience in     research and <font color="blue">development</font>, marketing, <font color="blue">distribution</font> and sales than we do</td>
    </tr>
    <tr>
      <td>Accordingly,  our  <font color="blue">competitors</font>  may  succeed in developing, marketing,     <font color="blue">distributing</font> and <font color="blue">selling products</font> and underlying <font color="blue">technologies</font> more rapidly     than  we  may</td>
    </tr>
    <tr>
      <td>These <font color="blue">competitive</font> products or <font color="blue">technologies</font> may be more     <font color="blue">effective</font> and useful or less costly than <font color="blue">bremelanotide</font>, <font color="blue">NeutroSpec </font>or our     other <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>In addition, academic institutions, hospitals,     <font color="blue"><font color="blue">government</font>al agencies</font> and other public and <font color="blue">private research organizations</font>     are  also  conducting  research  and may develop <font color="blue">competing products</font> or     <font color="blue">technologies</font> on their own or <font color="blue">through strategic alliances</font> or <font color="blue">collaborative</font>     <font color="blue">arrangement</font>s</td>
    </tr>
    <tr>
      <td>Our ability to achieve <font color="blue">significant</font> revenues from the sale of our future     <font color="blue">products will</font> depend, in part, on the ability of <font color="blue">healthcare providers</font> to     obtain adequate <font color="blue">reimbursement</font> from Medicare, Medicaid, <font color="blue">private insurers</font> and     other <font color="blue">healthcare payers</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">continuing efforts</font> of <font color="blue">government</font> and insurance companies, health     <font color="blue">maintenance organizations</font> and other payers of <font color="blue">healthcare costs</font> to contain or     <font color="blue">reduce costs</font> of healthcare may <font color="blue">adversely</font> affect our <font color="blue">future revenues</font> and     ability to achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">successfully</font> <font color="blue">commercialize</font>     our future <font color="blue">products will</font> depend, in <font color="blue">significant</font> part, on the extent to which     <font color="blue">healthcare providers</font> can obtain <font color="blue">appropriate</font> <font color="blue">reimbursement</font> levels for the     cost  of  our  products  and related treatment</td>
    </tr>
    <tr>
      <td>Third-party payers are     <font color="blue">increasingly challenging</font> the <font color="blue">prices charged</font> for <font color="blue">diagnostic</font> and <font color="blue">therapeutic</font>     products and related services</td>
    </tr>
    <tr>
      <td>Also, the trend towards managed health care     <font color="blue">in the US </font>and the <font color="blue">concurrent growth</font> of organizations such as HMOs could     control or <font color="blue"><font color="blue">significant</font>ly</font> influence the purchase of <font color="blue">healthcare services</font> and     products</td>
    </tr>
    <tr>
      <td>In addition, legislative proposals to <font color="blue">reform health care</font> or reduce     <font color="blue">government</font> insurance programs may result in <font color="blue">lower prices</font> or the actual     <font color="blue">inability</font> of <font color="blue">prospective customers</font> to purchase our <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>The cost     <font color="blue">containment measures</font> that <font color="blue">healthcare payers</font> and providers are <font color="blue">instituting</font>     and the effect of any <font color="blue">healthcare reform could materially</font> and <font color="blue">adversely</font>     affect our ability to operate profitably</td>
    </tr>
    <tr>
      <td>Furthermore, even if <font color="blue">reimbursement</font>     is available, it may not be <font color="blue">available at price levels sufficient</font> for us to     realize a positive return on our <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">could lose</font> our rights to NeutroSpec, <font color="blue">which could</font> <font color="blue">adversely</font> affect our     <font color="blue">potential revenues</font></td>
    </tr>
    <tr>
      <td>Our rights to a <font color="blue">key antibody used</font> in <font color="blue">NeutroSpec </font>are <font color="blue"><font color="blue">dependent</font> upon</font>     an <font color="blue">exclusive <font color="blue">license <font color="blue">agreement</font></font> with</font> <font color="blue">The Wistar Institute of Biology </font>and     Anatomy</td>
    </tr>
    <tr>
      <td>This <font color="blue"><font color="blue">agreement</font> contains specific performance criteria</font> and requires     us  to  pay  royalties  and make other payments</td>
    </tr>
    <tr>
      <td>Failure to meet these     <font color="blue">requirements</font>, or any other event of <font color="blue">default under</font> the <font color="blue">license <font color="blue">agreement</font></font>,     could lead to <font color="blue">termination</font> of the <font color="blue">license <font color="blue">agreement</font></font></td>
    </tr>
    <tr>
      <td>If the <font color="blue">license <font color="blue">agreement</font></font>     is terminated we will be unable to make or market NeutroSpec, in which case     we  may lose the value of our substantial <font color="blue">investment</font> in developing the     product, as well as any <font color="blue">future revenues</font> from selling NeutroSpec</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">adequately protect</font> or enforce our <font color="blue"><font color="blue">intellectual</font> property rights</font>     or  secure  rights to patents of others, the value of our <font color="blue">intellectual</font>     <font color="blue">property rights would diminish</font></td>
    </tr>
    <tr>
      <td>Our success, <font color="blue">competitive</font> position and <font color="blue">future revenues</font> will depend in     part  on  our ability and the <font color="blue">abilities</font> of our <font color="blue">licensors</font> to obtain and     maintain <font color="blue">patent protection</font> for our products, methods, processes and other     <font color="blue">technologies</font>, to preserve our <font color="blue">trade secrets</font>, to prevent <font color="blue">third parties</font> from     <font color="blue">infringing on</font> our <font color="blue">proprietary</font> rights and to operate <font color="blue">without infringing</font> the     <font color="blue">proprietary</font> rights of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font>:       • the degree and range of protection any patents will afford us against     <font color="blue">competitors</font>, including whether <font color="blue">third parties</font> will find ways to invalidate or     <font color="blue">otherwise circumvent</font> our patents;     • if and when patents will be issued;                                         13       _________________________________________________________________       [34]Table of <font color="blue">Contents       </font>• whether or not <font color="blue">others will</font> obtain patents claiming aspects similar to     those <font color="blue">covered by</font> our patents and patent <font color="blue">application</font>s; and     • whether we will need to <font color="blue">initiate litigation</font> or <font color="blue">administrative proceedings</font>,     which may be <font color="blue">costly whether</font> we win or lose</td>
    </tr>
    <tr>
      <td>If our products, methods, processes and other <font color="blue">technologies</font> infringe     the <font color="blue">proprietary</font> rights of other parties, we <font color="blue">could incur</font> substantial costs     and we may have to:       • obtain licenses, which may not be <font color="blue">available on</font> commercially reasonable     terms, if at all;     • redesign our products or processes to <font color="blue">avoid infringement</font>;     • stop using the subject matter claimed in the patents held by others;     • pay damages; or     • <font color="blue">defend litigation</font> or <font color="blue">administrative proceedings</font>, which may be costly     whether we win or lose, and <font color="blue">which could</font> result in a substantial diversion of     our <font color="blue"><font color="blue">management</font> resources</font></td>
    </tr>
    <tr>
      <td>If we are unable to keep our <font color="blue">trade secrets</font> confidential, our <font color="blue">technologies</font>     and other <font color="blue">proprietary</font> information may be used by others to <font color="blue">compete against</font>     us</td>
    </tr>
    <tr>
      <td>In addition to our <font color="blue">reliance on patents</font>, we attempt to protect our     <font color="blue">proprietary</font> <font color="blue">technologies</font> and <font color="blue">processes by relying on trade secret laws</font> and     <font color="blue">agreement</font>s with our employees and other persons who have access to our     <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>These <font color="blue">agreement</font>s and <font color="blue">arrangement</font>s may not provide     <font color="blue">meaningful protection</font> for our <font color="blue">proprietary</font> <font color="blue">technologies</font> and processes in the     event of <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font> of such information</td>
    </tr>
    <tr>
      <td>In addition,     our  <font color="blue">competitors</font>  may  <font color="blue">in<font color="blue">dependent</font>ly</font>  develop <font color="blue">substantially</font> equivalent     <font color="blue">technologies</font>  and  processes  or  gain  access to our <font color="blue">trade secrets</font> or     <font color="blue">technology</font>,  either of <font color="blue">which could</font> materially and <font color="blue">adversely</font> affect our     <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>Our collaboration <font color="blue">agreement</font>s may fail or be terminated <font color="blue">unexpectedly</font>, which     could result in <font color="blue">significant</font> delays and substantial increases in the cost of     our  research,  <font color="blue">development</font> and the <font color="blue">commercialization</font> of our potential     products</td>
    </tr>
    <tr>
      <td>We are party to various <font color="blue"><font color="blue">arrangement</font>s with</font> academic, <font color="blue">government</font>al and     <font color="blue">corporate partners</font></td>
    </tr>
    <tr>
      <td>The successful <font color="blue">development</font> and <font color="blue">commercialization</font> of the     potential  products <font color="blue">covered by</font> these <font color="blue">arrangement</font>s will depend upon the     ability  of  these  third  parties  to fully perform their <font color="blue">contractual</font>     <font color="blue">responsibilities</font></td>
    </tr>
    <tr>
      <td>If  any  of  these parties breaches or <font color="blue">unexpectedly</font>     terminates their <font color="blue">agreement</font> with us, or otherwise fails to conduct their     <font color="blue">activities</font> in a <font color="blue">timely manner</font>, the <font color="blue">development</font> or <font color="blue">commercialization</font> of our     <font color="blue">potential products</font> may be delayed</td>
    </tr>
    <tr>
      <td>We intend to continue to enter into <font color="blue">additional</font> <font color="blue">collaborations</font> to     develop and <font color="blue">commercialize</font> our <font color="blue">potential products</font> in the future</td>
    </tr>
    <tr>
      <td>We may not     be able to negotiate these <font color="blue">arrangement</font>s on favorable terms, if at all, and     these <font color="blue">relationship</font>s may not be successful</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">collaborative</font>     partners  may  pursue  <font color="blue">alternative</font> <font color="blue">technologies</font> or develop <font color="blue">alternative</font>     <font color="blue">compounds designed</font> to treat the <font color="blue">same diseases</font> that are the subject of their     <font color="blue">collaborative</font> programs with us</td>
    </tr>
    <tr>
      <td>We  may  incur  substantial  li<font color="blue">abilities</font>  and may be required to limit     <font color="blue">commercialization</font> of our products in response to <font color="blue"><font color="blue">product <font color="blue">liability</font></font> lawsuits</font></td>
    </tr>
    <tr>
      <td>The testing and marketing of <font color="blue">medical products entails</font> an inherent     risk  of <font color="blue">product <font color="blue">liability</font></font></td>
    </tr>
    <tr>
      <td>If we cannot <font color="blue">successfully</font> defend ourselves     against <font color="blue">product <font color="blue">liability</font></font> claims, we may incur substantial li<font color="blue">abilities</font> or be     required  to limit <font color="blue">commercialization</font> of our products or <font color="blue">cease clinical</font>     trials</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to obtain sufficient <font color="blue">product <font color="blue">liability</font></font> <font color="blue">insurance at</font> an     acceptable cost to protect against potential <font color="blue">product <font color="blue">liability</font></font> claims could     prevent or inhibit the <font color="blue">commercialization</font> of <font color="blue">pharmaceutical products</font> we     develop,  alone  or  with  <font color="blue">corporate <font color="blue">collaborators</font></font></td>
    </tr>
    <tr>
      <td>We currently carry     product/medical professional <font color="blue">liability</font> insurance, which includes <font color="blue">liability</font>     insurance for our <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We, or any <font color="blue">corporate <font color="blue">collaborators</font></font>, may     not  be able to obtain <font color="blue">insurance at</font> a <font color="blue">reasonable cost</font> or in sufficient     amounts,  if  at all</td>
    </tr>
    <tr>
      <td>Even if our <font color="blue">agreement</font>s with any <font color="blue">future corporate</font>     <font color="blue">collaborators</font>  entitle  us  to  <font color="blue">indemnification</font>  against  losses, such     <font color="blue">indemnification</font> may not be available or <font color="blue">adequate should</font> any claim arise</td>
    </tr>
    <tr>
      <td>We  are  highly  <font color="blue">dependent</font>  on our <font color="blue"><font color="blue">management</font> team</font> and <font color="blue">senior research</font>     <font color="blue">professionals</font></td>
    </tr>
    <tr>
      <td>We  are a <font color="blue">relatively</font> small company</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> our     continued  ability  to  attract,  retain and <font color="blue">motivate highly qualified</font>     <font color="blue">management</font> and <font color="blue">scientific personnel</font>, including <font color="blue">executive officers</font> and senior     members of <font color="blue">management</font> that oversee our <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue">certain research personnel</font> possess <font color="blue">significant</font> technical expertise and     experience relevant to our <font color="blue">development</font> programs and we will need to hire     <font color="blue">additional</font>                                         14       _________________________________________________________________       [35]Table of <font color="blue">Contents       </font>personnel to expand our research and <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Our success     <font color="blue">also depends on</font> our ability to develop and maintain <font color="blue">relationship</font>s with     <font color="blue">consultants</font> and <font color="blue">scientific advisors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for personnel is intense</td>
    </tr>
    <tr>
      <td>If we lose the services of <font color="blue">existing personnel</font> or fail to attract required     <font color="blue">new personnel</font>, our <font color="blue">development</font> programs could be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>If we acquire other products, <font color="blue">technologies</font> or <font color="blue">operations</font>, we will incur a     variety  of  risks  that  could  <font color="blue">adversely</font> affect our current business     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are, and expect to continue, actively searching for certain     products and <font color="blue">technologies</font> to license or acquire, now or in the future</td>
    </tr>
    <tr>
      <td>If we     are successful in identifying a product or <font color="blue">technology</font> for <font color="blue">acquisition</font>, we     may  require  substantial funds for such an <font color="blue">acquisition</font> and subsequent     <font color="blue">development</font> or <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>We do not know whether any <font color="blue">acquisition</font>     will be consummated in the future</td>
    </tr>
    <tr>
      <td>Any such <font color="blue">acquisition</font> may expose us to     <font color="blue">additional</font> risks, including the need to devote <font color="blue">significant</font> resources to new     <font color="blue">activities</font> and to raise <font color="blue">additional</font> funds</td>
    </tr>
    <tr>
      <td><font color="blue">Shareholders  </font>may experience <font color="blue">dilution from</font> the exercise of outstanding     options and warrants</td>
    </tr>
    <tr>
      <td><font color="blue">As of June </font>30, 2006, options and warrants to purchase 15cmam568cmam859     shares of <font color="blue">common stock</font> were <font color="blue">outstanding at various exercise prices ranging</font>     from dlra1dtta00 per share to dlra8dtta00 per share</td>
    </tr>
    <tr>
      <td>The issuance or <font color="blue">potential issuance</font>     and sale of <font color="blue">common stock</font> upon the exercise of these options and <font color="blue">warrants may</font>     <font color="blue">adversely</font>  affect  the  market  price of our <font color="blue">common stock</font> or result in     substantial dilution to our <font color="blue">existing <font color="blue">stockholders</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">management</font> and principal <font color="blue">stockholders</font> together control approximately 20prca     of our <font color="blue">voting securities</font> and <font color="blue">such concentration</font> of <font color="blue">ownership could delay</font> or     prevent a change in control</td>
    </tr>
    <tr>
      <td>As  of  June  30,  2006,  our <font color="blue">executive officers</font> and <font color="blue">directors</font>     <font color="blue">beneficially</font> own approximately 5prca of our <font color="blue">voting securities</font> and our 5prca or     greater  <font color="blue">stockholders</font> <font color="blue">beneficially</font> own approximately 15prca of our voting     securities</td>
    </tr>
    <tr>
      <td>These  <font color="blue">stockholders</font>,  acting  together,  may  be  able to     <font color="blue"><font color="blue">significant</font>ly</font>  influence  any  matters  submitted  for <font color="blue">approval by</font> our     <font color="blue">stockholders</font>, including the election of <font color="blue">directors</font>, delaying or preventing a     change  of  control,  and  the  <font color="blue">consideration</font> of <font color="blue"><font color="blue">transaction</font>s</font> in which     <font color="blue">stockholders</font> might otherwise receive a premium for their <font color="blue">shares over then</font>     <font color="blue">current <font color="blue">market price</font>s</font></td>
    </tr>
    <tr>
      <td>Anti-takeover provisions of <font color="blue">Delaware </font>law and our <font color="blue">charter documents may</font> make     potential <font color="blue">acquisition</font>s more <font color="blue">difficult</font> and could result in the <font color="blue">entrenchment</font>     of <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>We  are  <font color="blue">incorporated</font> in Delaware</td>
    </tr>
    <tr>
      <td>Anti-takeover provisions of     <font color="blue">Delaware </font>law and our <font color="blue">charter documents may</font> make a change in control or     efforts to remove <font color="blue">management</font> more <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>Also, under <font color="blue">Delaware </font>law, our     board  of <font color="blue">directors</font> may adopt <font color="blue">additional</font> anti-takeover measures</td>
    </tr>
    <tr>
      <td>Under     Section 203 of the <font color="blue">Delaware </font>General Corporation Law, a <font color="blue">corporation</font> may not     engage in a business <font color="blue">combination</font> with an “<font color="blue">interested stockholder</font>” for a     period of <font color="blue">three years</font> after the date of the <font color="blue">transaction</font> in which the person     <font color="blue">first becomes</font> an “<font color="blue">interested stockholder</font>,” unless the business <font color="blue">combination</font>     is approved in a <font color="blue">prescribed manner</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">charter authorizes us</font> to issue up to 10cmam000cmam000 shares of     <font color="blue">preferred stock</font> and to determine the terms of those shares of <font color="blue">stock without</font>     any <font color="blue">further action by</font> our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If we exercise this power, it could     be more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire a majority of our outstanding     <font color="blue">voting stock</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">equity incentive</font> plans <font color="blue">generally</font> permit us to     <font color="blue">accelerate</font> the vesting of <font color="blue">options granted under</font> these plans in the event of     a change of control</td>
    </tr>
    <tr>
      <td>If we <font color="blue">accelerate</font> the vesting of options, this action     could make an <font color="blue">acquisition</font> more costly</td>
    </tr>
    <tr>
      <td>The  <font color="blue">application</font>  of these <font color="blue">provisions could</font> have the effect of     delaying or preventing a change of control, <font color="blue">which could</font> <font color="blue">adversely</font> affect the     <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our stock price is, and we expect it to remain, volatile, <font color="blue">which could</font> limit     investors’ ability to <font color="blue">sell stock at</font> a profit</td>
    </tr>
    <tr>
      <td>The <font color="blue">volatile price</font> of our stock makes it <font color="blue">difficult</font> for investors to     predict the value of their <font color="blue">investment</font>, to <font color="blue">sell shares at</font> a profit at any     given time, or to plan purchases and sales in advance</td>
    </tr>
    <tr>
      <td>A variety of factors     may affect the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>These include, but are not     limited to:       • publicity regarding actual or <font color="blue">potential clinical</font> results relating to     products under <font color="blue">development</font> by our <font color="blue">competitors</font> or us;     • delay or failure in initiating, completing or analyzing pre-clinical or     <font color="blue">clinical trials</font> or unsatisfactory design or result of these trials;     • <font color="blue">achievement</font> or rejection of <font color="blue"><font color="blue">regulatory</font> approval</font>s by our <font color="blue">competitors</font> or by     us;                                         15       _________________________________________________________________       [36]Table of <font color="blue">Contents       </font>• <font color="blue">announcements</font> of <font color="blue">technological</font> innovations or <font color="blue">new commercial products by</font>     our <font color="blue">competitors</font> or by us;     • <font color="blue">development</font>s concerning <font color="blue">proprietary</font> rights, including patents;     • <font color="blue">development</font>s concerning our <font color="blue">collaborations</font>;     • <font color="blue">regulatory</font> <font color="blue">development</font>s <font color="blue">in the US </font>and foreign countries;     • economic or other crises and other <font color="blue">external factors</font>;     •  period-to-period  <font color="blue">fluctuations</font>  in our revenue and other results of     <font color="blue">operations</font>;     • changes in financial estimates <font color="blue">by <font color="blue">securities analysts</font></font>; and     • sales of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We will not be able to control many of these factors, and we believe     that  period-to-period  <font color="blue">comparisons</font>  of our financial results will not     <font color="blue">necessarily</font> be <font color="blue">indicative</font> of our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>If our revenues, if     any, in any <font color="blue">particular period</font> do not <font color="blue">meet <font color="blue">expectations</font></font>, we may not be able     to adjust our <font color="blue">expenditures</font> in that period, <font color="blue">which could</font> cause our operating     results to <font color="blue">suffer further</font></td>
    </tr>
    <tr>
      <td>If our operating results in any <font color="blue">future period</font>     fall below the <font color="blue">expectations</font> of <font color="blue">securities analysts</font> or investors, our stock     <font color="blue">price may fall by</font> a <font color="blue">significant</font> amount</td>
    </tr>
    <tr>
      <td>In  addition,  the <font color="blue">stock market</font> in general, and the market for     <font color="blue">bio<font color="blue">technology</font> companies</font> in particular, has experienced <font color="blue">extreme price</font> and     volume <font color="blue">fluctuations</font> that may have <font color="blue">been unrelated</font> or <font color="blue">disproportionate</font> to the     operating  performance of individual companies</td>
    </tr>
    <tr>
      <td>These <font color="blue">broad market</font> and     <font color="blue">industry factors may seriously harm</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font>,     <font color="blue">regardless</font> of our operating performance</td>
    </tr>
    <tr>
      <td>We expect to sell <font color="blue">additional</font> <font color="blue">equity securities</font>, which will cause dilution</td>
    </tr>
    <tr>
      <td>We expect to sell more <font color="blue">equity securities</font> in the future to obtain     cash for <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may sell these <font color="blue">securities at</font> a discount to the     market  price</td>
    </tr>
    <tr>
      <td>Any <font color="blue">future sales</font> of <font color="blue">equity will dilute</font> the holdings of     <font color="blue">existing <font color="blue">stockholders</font></font>, possibly reducing the value of their <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We do not intend to <font color="blue">pay <font color="blue">cash dividends</font></font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We do not anticipate paying any <font color="blue">cash dividends</font> in the foreseeable     future and intend to retain any <font color="blue">future earnings</font> for the <font color="blue">development</font> and     expansion of our business</td>
    </tr>
    <tr>
      <td>In addition, the terms of existing or future     <font color="blue">agreement</font>s  may  limit  our  ability  to <font color="blue">pay dividends</font></td>
    </tr>
    <tr>
      <td>Therefore, our     <font color="blue">stockholders</font> will not receive a return on their <font color="blue">shares unless</font> the value of     their <font color="blue">shares increases</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">broad <font color="blue">discretion</font> over</font> the use of <font color="blue">available cash</font> and may not realize     an <font color="blue">adequate return</font></td>
    </tr>
    <tr>
      <td>We have considerable <font color="blue">discretion</font> in the <font color="blue">application</font> of <font color="blue">available cash</font>     and have not fixed the amounts that we will apply to <font color="blue">various corporate</font>     purposes, including potential <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>We <font color="blue">may use cash</font> for purposes     that do not yield a <font color="blue">significant</font> return, if any, for our <font color="blue">stockholders</font></td>
    </tr>
  </tbody>
</table>